Our data show that PI3K/AKT inhibition in these pancreatic cancer cells results in a decrease in BCL-2 and an increase in BAX without effect on other members of the BCL-2 family; furthermore, this effect appears limited to those cell lines that demonstrate AKT activation under basal conditions. The gene discussed is AKT1; the disease is familial pancreatic carcinoma.